Caroline Seymour

Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Cabozantinib Efficacy Prompts CABINET Trial Unblinding in Advanced Pancreatic and Extra-Pancreatic NETs

August 24th 2023

Interim data from the phase 3 CABINET trial demonstrated significant improvement in progression-free survival with cabozantinib vs placebo in patients with advanced pancreatic or extra-pancreatic neuroendocrine tumors following progression on prior systemic therapy.

Olaparib Plus Abiraterone Acetate Receives Japanese Approval for BRCA-Mutant mCRPC

August 24th 2023

The Japanese Ministry of Health, Labour, and Welfare has approved the combination of olaparib plus abiraterone acetate and prednisone or prednisolone for the treatment of adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.

Tiragolumab Plus Atezolizumab Falls Short in Unexpected OS Analysis in PD-L1–High NSCLC

August 23rd 2023

The addition of the investigational anti-TIGIT immunotherapy tiragolumab to atezolizumab demonstrated a numerical but not statistically significant improvement in overall survival vs atezolizumab alone as frontline therapy for patients with PD-L1–high, locally advanced or metastatic non–small cell lung cancer.

Personalized Neoantigen Vaccine Induces Continued Responses in Pretreated, Advanced HCC

August 22nd 2023

Second-line treatment with GNOS-PV02 plus plasmid-encoded interleukin-12 followed by electroporation elicited complete molecular response detected via circulating tumor DNA in 4 additional patients with advanced hepatocellular carcinoma enrolled in the phase 1b/2a GT-30 study.

FDA Places Second Partial Clinical Hold on AML Enrollment for Magrolimab Trials

August 21st 2023

The FDA has placed another partial clinical hold on the enrollment of new patients in United States clinical trials evaluating the potential first-in-class investigational anti-CD47 immunotherapy magrolimab for the treatment of acute myeloid leukemia.

Atezolizumab Plus Cabozantinib Improves PFS in Hormone Therapy–Pretreated mCRPC

August 21st 2023

The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer and measurable soft tissue disease following 1 prior novel hormonal therapy, meeting one of the primary end points in the primary analysis of the phase 3 CONTACT-02 trial.

TNB-486 Elicits 91% CR Rate in Heavily Pretreated, High-Risk Follicular Lymphoma

August 19th 2023

TNB-486 demonstrated sustained antitumor activity in all but 1 patient with relapsed/refractory follicular lymphoma, regardless of CD20 status, as well as number and type of prior therapy.

Belzutifan Improves PFS in Pretreated Advanced RCC

August 18th 2023

Treatment with belzutifan demonstrated a statistically significant and clinically meaningful improvement in progression-free survivalcompared with everolimus in patients with advanced renal cell carcinoma that has progressed on prior PD-1/PD-L1 and VEGF inhibitors, in sequence or in combination.

Frontline Quizartinib Plus Chemotherapy Shows Curative Potential in FLT3-ITD Wild-Type AML

August 17th 2023

The addition of quizartinib to standard induction and consolidation chemotherapy with idarubicin plus cytarabine followed by maintenance therapy led to an improvement in event-free survival compared with placebo plus chemotherapy in patients with FLT3-ITD wild-type acute myeloid leukemia.

FDA Grants Orphan Drug Designation to NXP800 for Cholangiocarcinoma

August 17th 2023

The FDA has granted an orphan drug designation to NXP800 for the treatment of patients with cholangiocarcinoma.

MB-106 Shows Continued Activity in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

August 16th 2023

MB-106, a first-in-class, CD20-targeted autologous CAR T-cell therapy, led to durable clinical responses with low-grade cytokine release syndrome in patients with indolent lymphoma.

Copper 64 PSMA I&T Meets Coprimary End Points of SOLAR Trial in Metastatic Prostate Cancer

August 15th 2023

Use of Copper 64 PSMA I&T for PET/CT imaging met the threshold for significance regarding region-level correct localization rate and patient-level correct detection rate in patients with histologically confirmed metastatic prostate cancer, meeting the coprimary end points of the phase 2 SOLAR trial.

FDA Grants Orphan Drug Designation to Quratusugene Ozeplasmid for Small Cell Lung Cancer

August 14th 2023

The FDA has granted an orphan drug designation to quratusugene ozeplasmid (Reqorsa) for the treatment of patients with small cell lung cancer.

Extended Treatment With CAEL-101 Plus SOC Therapy Proves Safe in Light-Chain Amyloidosis

August 12th 2023

The addition of the chimeric monoclonal antibody CAEL-101 to standard therapy with cyclophosphamide, bortezomib, and dexamethasone with or without daratumumab demonstrated a manageable toxicity profile with prolonged clinical benefit in patients with amyloid light-chain amyloidosis.

FDA Approves Niraparib Plus Abiraterone Acetate for BRCA+ mCRPC

August 11th 2023

The FDA has approved niraparib plus abiraterone acetate, given with prednisone, for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive, metastatic castration-resistant prostate cancer, as detected by an FDA-approved test.

FDA Allows Continuation of Phase 1/2 Trial of ONCT-534 in mCRPC

August 11th 2023

The FDA has approved a study may proceed letter in advance of its 30-day review period to Oncternal Therapeutics for its phase 1/2 study evaluating ONCT-534, a novel dual-action AR inhibitor in patients with mCRPC who have relapsed or are refractory to approved AR signaling inhibitors.

Zipalertinib Plus Chemotherapy Moves to Phase 3 Study in EGFR Exon 20 Insertion+ NSCLC

August 4th 2023

The safety and efficacy of zipalertinib plus platinum-based chemotherapy will be compared with platinum-based chemotherapy alone in patients with treatment-naïve, locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations in the phase 3 REZILIENT3 trial.

FDA Issues CRL to BLA Resubmission for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

August 4th 2023

The FDA has released a complete response letter to its biologics license application resubmission, indicating that it needs more data to support approval for remestemcel-L for the treatment of pediatric patients with steroid-refractory acute graft-vs-host disease.

FDA Grants Orphan Drug Designation to ABM-1310 for BRAF V600–Mutant Glioblastoma

August 3rd 2023

The FDA has granted an orphan drug designation to ABM-1310 for the treatment of patients with BRAF V600–mutant glioblastoma.

Data With Novel Agents Prompt Treatment Sequencing Discussions in MCL and CLL

August 3rd 2023

Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.